Cel-Sci (CVM +3.5%) has rallied after issuing a shareholder letter in which the company expressed confidence about the outlook for Phase III trials of its Multikine immunotherapy treatment for head and neck cancer. The company also said it plans to increase the number of patient recruitment centers for the trials to at least 50, comapred with a current 36.
From other sites
at Zacks.com (Mar 9, 2015)
at Zacks.com (Mar 4, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs